# Spyre Therapeutics (SYRE) — Analyst Forecast

SYRE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/syre/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 14 | 1 | 0 | 15 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $110.00 | $120.86 | $130.00 | 7 |

Last price $80.10 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | UBS | Initiated Coverage | Buy | $120.00 |
| Oct 1, 2026 | BTIG | Maintained | Buy | $121.00 |
| Oct 1, 2026 | JP Morgan | Initiated Coverage | Overweight | $110.00 |
| Sep 9, 2026 | Wedbush | Maintained | Outperform | $123.00 |
| Sep 8, 2026 | BTIG | Maintained | Buy | $121.00 |
| Aug 26, 2026 | BTIG | Maintained | Buy | $121.00 |
| Aug 26, 2026 | Wedbush | Maintained | Outperform | $123.00 |
| Aug 26, 2026 | Deutsche Bank | Maintained | Buy | $127.00 |
| Aug 11, 2026 | BTIG | Maintained | Buy | $132.00 |
| Aug 5, 2026 | Wedbush | Maintained | Outperform | $130.00 |
| Aug 5, 2026 | Guggenheim | Maintained | Buy | $130.00 |
| Aug 5, 2026 | Wells Fargo | Maintained | Overweight | $115.00 |
| Jul 28, 2026 | Wolfe Research | Downgraded | Outperform → Peer Perform | — |
| Jul 13, 2026 | Mizuho | Maintained | Outperform | $120.00 |
| Jun 23, 2026 | Deutsche Bank | Maintained | Buy | $135.00 |
| Jun 15, 2026 | BTIG | Maintained | Buy | $112.00 |
| Jun 4, 2026 | Deutsche Bank | Maintained | Buy | $115.00 |
| May 6, 2026 | Stifel | Maintained | Buy | $107.00 |
| May 6, 2026 | Citigroup | Maintained | Buy | $97.00 |
| Apr 17, 2026 | Jones Trading | Maintained | Buy | $95.00 |

## Frequently Asked Questions

### What is the price target for SYRE stock?

The average 12-month analyst price target for Spyre Therapeutics (SYRE) is $120.86, with a high estimate of $130.00 and a low of $110.00, across 7 analysts.

### Is SYRE a buy, sell, or hold?

Analysts covering Spyre Therapeutics currently average a Buy rating: 14 buy, 1 hold and 0 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for SYRE?

The average price target of $120.86 implies 50.88% upside from the last price of $80.10.

### What is the latest analyst rating on SYRE?

On Oct 12, 2026, UBS initiated coverage of Spyre Therapeutics at Buy with a price target of $120.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).